0
Articles |

Comparison of Early IgM-Enriched Immunoglobulin vs Polyvalent IgG Administration in Score-Identified Postcardiac Surgical Patients at High Risk for Sepsis

Günter Pilz; Roland Appel; Eckart Kreuzer; Karl Werdan
Author and Funding Information

Affiliations: From the Department of Medicine I, Grosshadern University Hospital, University of Munich, Munich, Germany,  From the Department of Cardiac Surgery, Grosshadern University Hospital, University of Munich, Munich, Germany

Affiliations: From the Department of Medicine I, Grosshadern University Hospital, University of Munich, Munich, Germany,  From the Department of Cardiac Surgery, Grosshadern University Hospital, University of Munich, Munich, Germany


1997 by the American College of Chest Physicians


Chest. 1997;111(2):419-426. doi:10.1378/chest.111.2.419
Text Size: A A A
Published online

Abstract

Study objective: To address the relevance of the IgM component in polyvalent immunoglobulins in sepsis treatment by comparison of the clinical course under polyvalent IgG vs IgGMA therapy in postcardiac surgical patients at high risk for sepsis and to reassess the prognostic validity of sequential changes in acute physiology and chronic health evaluation (APACHE II) scores during treatment.

Design: Prospective, randomized clinical trial.

Setting: Cardiac surgical ICU in a university hospital.

Patients: Among 870 consecutive patients after elective open-heart surgery, 29 (3.3%) met the previously validated high-risk criterion (APACHE II score ≥24 on the first postoperative day) with a mean APACHE II score-predicted mortality risk of 63%.

Interventions: In addition to standard therapy, 27 of these patients were randomized to receive commercially available IV IgG (Polyglobin N, n=14, total dosage: 18 mL/kg) or IgGMA (Pentaglobin, n=13, total dosage: 15 mL/kg).

Measurements and results: The two groups were comparable in baseline disease severity and concurrent therapy. The extent of score-quantified improvement in disease severity during treatment was similar in both groups (mean fall in APACHE II scores within 4 days: IgG, −6.9; IgGMA, −5.2), as were score-defined improvement rates (rate of patients with score decrease ≥7 within 4 days: IgG, 57%; IgGMA, 54%) and in-hospital mortality (IgG, 29%; IgGMA, 31%) (all p=NS). There was a strong association between the decrease over time in APACHE II scores during therapy and prognosis (mortality rates in patients with vs without score-assessed improvement: 0% vs 67%, p=0.0002).

Conclusions: IgG and IgGMA were associated with a comparable improvement in disease severity in score-identified postcardiac surgical patients at high risk for sepsis. Given the design as an efficacy rather than an equivalence study, this hypothesis derived from our results needs independent validation in larger trials. Sequential APACHE II score changes were reconfirmed as a prognostically valid quantitative measure of disease progress during sepsis therapy.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543